Cargando…

Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis

Brincidofovir is an oral antiviral in development for prevention of cytomegalovirus disease. Cytomegalovirus genotyping results from a phase 2 trial comparing brincidofovir to placebo for prophylaxis against cytomegalovirus infection in hematopoietic cell transplant recipients provided initial data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lanier, E. Randall, Foster, Scott, Brundage, Tom, Chou, Sunwen, Prichard, Mark N., Kleiboeker, Steven, Wilson, Chad, Colville, Donella, Mommeja-Marin, Herve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907407/ https://www.ncbi.nlm.nih.gov/pubmed/26941282 http://dx.doi.org/10.1093/infdis/jiw073

Ejemplares similares

Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies
por: Tippin, Timothy K., et al.
Publicado: (2016)

The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak
por: Foster, Scott A., et al.
Publicado: (2017)

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
por: Marty, Francisco M., et al.
Publicado: (2018)

Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection
por: Chou, Sunwen, et al.
Publicado: (2020)

Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection
por: Vial, Romain, et al.
Publicado: (2017)

Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus
por: Parker, Scott, et al.
Publicado: (2014)

Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
por: Gill, Rachel B, et al.
Publicado: (2009)

Experimental Treatment of Ebola Virus Disease with Brincidofovir
por: Dunning, Jake, et al.
Publicado: (2016)

Viral and Cell Cycle–Regulated Kinases in Cytomegalovirus-Induced Pseudomitosis and Replication
por: Hertel, Laura, et al.
Publicado: (2007)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice
por: Prichard, Mark N, et al.
Publicado: (2006)

Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection
por: Faure, Emmanuel, et al.
Publicado: (2016)

Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection: Erratum
Publicado: (2017)

Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection
por: Chan, Shuk Ying, et al.
Publicado: (2021)

Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies
por: Vyas, Ami, et al.
Publicado: (2022)

Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects
por: Wire, Mary Beth, et al.
Publicado: (2017)

Brincidofovir (CMX001) for the Treatment of Severe Adenoviral Pneumonia in Kidney Transplant Recipient
por: Sudhindra, Praveen, et al.
Publicado: (2019)

Association of Cytomegalovirus DNA and Immunologic Markers of Cardiovascular Disease
por: Garg, Ankita, et al.
Publicado: (2019)

A Prospective Study of Cytomegalovirus-Specific Cell-Mediated Immune Monitoring and Cytomegalovirus Infection in Patients With Active Systemic Lupus Erythematosus Receiving Immunosuppressants
por: Bruminhent, Jackrapong, et al.
Publicado: (2021)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

In Utero Activation of Natural Killer Cells in Congenital Cytomegalovirus Infection
por: Vaaben, Anna V, et al.
Publicado: (2022)

The Excess Burden of Cytomegalovirus in African American Communities: A Geospatial Analysis
por: Lantos, Paul M., et al.
Publicado: (2015)

Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency
por: Popping, Stephanie, et al.
Publicado: (2019)

Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation
por: Van Genechten, T., et al.
Publicado: (2020)

Brincidofovir is a robust replication inhibitor against African swine fever virus in vivo and in vitro
por: Guo, Shibang, et al.
Publicado: (2023)

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus
por: Muthumani, Karuppiah, et al.
Publicado: (2016)

Human Cytomegalovirus Up-Regulates Endothelin Receptor Type B: Implication for Vasculopathies?
por: Yaiw, Koon-Chu, et al.
Publicado: (2015)

Molecular and Culture-Based Bronchoalveolar Lavage Fluid Testing for the Diagnosis of Cytomegalovirus Pneumonitis
por: Tan, Susanna K., et al.
Publicado: (2016)

Cardiac Microvascular Dysfunction in Women Living With HIV Is Associated With Cytomegalovirus Immunoglobulin G
por: Knudsen, Andreas, et al.
Publicado: (2018)

Cytomegalovirus Latent Infection is Associated with an Increased Risk of COVID-19-Related Hospitalization
por: Alanio, Cécile, et al.
Publicado: (2022)

Outcomes of Cytomegalovirus Viremia Treatment in Critically Ill Patients With COVID-19 Infection
por: Schoninger, Scott, et al.
Publicado: (2022)

Cytomegalovirus Viremia Predicts Postdischarge Mortality in Kenyan HIV-Exposed Uninfected Children( )
por: Pavlinac, Patricia B, et al.
Publicado: (2022)

1421. IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects
por: Naderer, Odin, et al.
Publicado: (2018)

Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model
por: Hutson, Christina L., et al.
Publicado: (2021)

Are the Healthy Vulnerable? Cytomegalovirus Seropositivity in Healthy Adults Is Associated With Accelerated Epigenetic Age and Immune Dysregulation
por: Poloni, Chad, et al.
Publicado: (2021)

Cytomegalovirus Retinitis Screening and Treatment in Human Immunodeficiency Virus Patients in Malawi: A Feasibility Study
por: Ocieczek, Paulina, et al.
Publicado: (2019)

Are the Patterns of Cytomegalovirus Viral Load Seen After Solid Organ Transplantation Affected by Circadian Rhythm?
por: Rafferty, Hannah, et al.
Publicado: (2022)

Human Cytomegalovirus Immunoglobulin G Response and Pulmonary Tuberculosis in Adolescents: A Case-Control Study
por: Swanepoel, Jeremi, et al.
Publicado: (2023)

Incidence of Cytomegalovirus Primary and Secondary Infection in Adolescent Girls: Results From a Prospective Study
por: Paris, Robert, et al.
Publicado: (2023)

Benefits of Polymerase Chain Reaction Combined With Culture for the Diagnosis of Bone and Joint Infections: A Prospective Test Performance Study
por: Jacquier, Hervé, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_98hm86eisdba5uj5vpc99pfqlr